Navigation Links
TARGETED GENE DELIVERY IN VIVO: Rexin-G Monotherapy Reveals Significant Biological Activity Without Toxicity in Chemo-Resistant Metastatic Breast Cancer (ASCO 2008)
Date:5/22/2008

SAN MARINO, Calif., May 22 /PRNewswire/ -- Epeius Biotechnologies announced today the promising results of an on-going United States-based Phase I/II study of Rexin-G for metastatic breast cancer that is refractory to conventional chemotherapy (J Clin Oncol 26:14509, 2008). This clinical trial employed intra-patient dose-escalations of Rexin-G given i.v. two to three times a week for 4 weeks, with doses ranging from 2 x 10e11 cfu to 6 x 10e11 cfu per week. The goal of the adaptive trial design is to confirm the over-all safety of Rexin-G and to determine the optimal dosing regimen for Rexin-G that would document the significant clinical benefits required to support a Phase II pivotal study.

The interim results of this Phase I/II study of targeted gene delivery in vivo are very encouraging -- intravenous infusions of Rexin-G demonstrated significant biological activity without toxicity in patients with rapidly progressive chemo-resistant breast cancer. Once the general safety of repeated infusions of Rexin-G was documented, the FDA approved across the board intra-patient dose-escalations in order to gain better tumor control. These escalating doses of Rexin-G were associated with stabilization of disease, using both RECIST and International PET criteria, significant reductions in CA 15.3 levels, a median progression-free survival of 6 months (RECIST) and a median over-all survival of greater than 7 months with all patients surviving at the 8-month follow-up period. No dose-limiting toxicity was observed, even at the higher doses of Rexin-G, thus confirming that repeated infusions of Rexin-G are safe and well-tolerated.

According to Dr. Erlinda M. Gordon, Medical Director of Epeius, "The importance of these dose-escalation studies -- which clearly establish safety before escalating to more potent tumoricidal levels -- is a primary concern in the development of a new genetic medicine like Rexin-G." Taken together with the results of previous studie
'/>"/>

SOURCE Epeius Biotechnologies
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Launch of Highly Targeted Cancer Treatment Tasigna(R) (nilotinib) Offers Potential Lifeline to Ph+ CML Patients Intolerant or Resistant to Existing Therapies, Including Glivec(R) (imatinib)
2. Phosphagenics Reports Positive Pre-clinical Results for Targeted Delivery of Lidocaine
3. Semafores PI3 Kinase Inhibitor SF1126 is a Vascular Targeted Conjugate in Phase I Clinical Trials in Solid Tumors and Multiple Myeloma
4. Everolimus (RAD001) Significantly Extends Progression-Free Survival in Advanced Kidney Cancer Patients After Failure of Other Targeted Therapy
5. Oral Talactoferrin Alfa Improves Overall Survival in Patients With Refractory Non-Small Cell Lung Cancer: Final Phase 2 Study Results Presented at the 8th Annual Targeted Therapies for the Treatment Of Lung Cancer Meeting
6. Oncology Drug Development Update - Molecular Profiling Redefines the Nature of Malignancy and Increases the Adoption of Targeted Therapeutics
7. Epeius Biotechnologies Applauds the Belated Scholarship of Their Academic Contemporaries in 2007, As Targeted Gene Therapy Comes of Age in Clinical Medicine
8. ASEAN News: Epeius Biotechnologies Gains Commercial Approval for Rexin-G(R), a Tumor-Targeted Gene-Based Medicine for Metastatic Cancer
9. ARCA Discovery Announces Data Demonstrating Potential for Bucindolol as Targeted Therapy in Heart Failure, Atrial Fibrillation, and Ventricular Arrhythmia
10. Targeted Nanoparticles Offer Promise in the Battle Against Cancer
11. Microarray Sequence Capture Speeds Large-Scale Resequencing of Targeted Genomic Regions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... 21, 2014  Heated dialogue in recent months about ... cancer treatments to Gilead,s new hepatitis C drug Harvoni® ... world questioning what it means to put a price ... And while drug pricing is one of the ... both a general business and ethical standpoint – it ...
(Date:11/21/2014)... 21, 2014  PTC Therapeutics, Inc. (NASDAQ: PTCT ... Technology Award for Vision, Innovation, and Leadership has been awarded ... This award recognizes an individual who has had a significant ... for several decades. "I am honored ... Stuart Peltz , Ph.D., CEO of PTC Therapeutics, Inc. "When ...
(Date:11/21/2014)... Clementia Pharmaceuticals, Inc.  announced ... has granted Orphan Medicinal Product Designation for ... the treatment of fibrodysplasia ossificans progressiva (FOP). ... disease characterized by painful, recurrent episodes of ... bone formation. This process, known as heterotopic ...
Breaking Medicine Technology:"The Price of Global Health" Tackles Worldwide Drug-Pricing Debate 2"The Price of Global Health" Tackles Worldwide Drug-Pricing Debate 3"The Price of Global Health" Tackles Worldwide Drug-Pricing Debate 4"The Price of Global Health" Tackles Worldwide Drug-Pricing Debate 5PTC Therapeutics Announces CEO, Dr. Stuart Peltz Recipient of The New Jersey Technology Council's 2014 Legend of Technology Award 2PTC Therapeutics Announces CEO, Dr. Stuart Peltz Recipient of The New Jersey Technology Council's 2014 Legend of Technology Award 3Clementia Pharmaceuticals Receives EMA Orphan Medicinal Product Designation for Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva 2Clementia Pharmaceuticals Receives EMA Orphan Medicinal Product Designation for Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva 3
(Date:11/22/2014)... PITTSBURGH, PA (PRWEB) November 22, 2014 “Due ... cane,” said an inventor, from Gurnee, Ill. “While using the ... could be and I thought there needed to be a ... He invented the SPIKE BLOCK. , The SPIKE BLOCK offers ... doing so, it would help to reduce injuries and damage ...
(Date:11/22/2014)... In order to provide better services, LunaDress has updated ... The business knows that a suitable cocktail party dress is ... Now, the party dresses supplier’s high quality items are offered ... company in fashion industry, LunaDress understands that it is not ... it always raises the professional level and innovation ability. The ...
(Date:11/22/2014)... 22, 2014 "My friend went in ... by the machine," said an inventor from Cambria Heights, ... go back a second time because the first results ... She developed the patent-pending MAMO EASY to offer a ... design saves the patient from the pain normally involved ...
(Date:11/22/2014)... Domestic farmgate milk and dairy ... due to a fall in demand for ... amid the global financial crisis. However, these declines ... dairy manufacturers on the international scene. Strong growth ... growth, primarily due to supply constraints in some ...
(Date:11/22/2014)... The topic of B&D Rockeries’ latest publication ... The article states that, “While they give off the appearance ... go into creating this powerful look.” , One of the ... choosing which kind of block matches your home environment and ... “The two main options are concrete and stone blocks. But ...
Breaking Medicine News(10 mins):Health News:LunaDress Unveils Fabulous Cocktail Party Dresses 2Health News:Butter and Dairy Product Manufacturing in Australia Industry Market Research Report Now Updated by IBISWorld 2Health News:Butter and Dairy Product Manufacturing in Australia Industry Market Research Report Now Updated by IBISWorld 3Health News:Butter and Dairy Product Manufacturing in Australia Industry Market Research Report Now Updated by IBISWorld 4Health News:5 Step Installment of Block Retaining Walls is Topic of Latest Article by B&D Rockeries 2
... The Health Coalition on Liability and Access released a ... on the state and federal level. The report detailed ... passed laws limiting non-economic damages, while also acknowledging the ... to be enacted and is unlikely in the 111th ...
... are many targets now for interfering with the process , , ... from infected to uninfected immune system T-cells has been captured ... could lead to new ways to block the transmission of ... have focused on free- roaming viruses, but this study shows ...
... Test drives of the Simulated Impaired Driving Experience(R), (SIDNE(R)), ... be attending the Lifesavers conference at the Gaylord Opryland ... 30 and 31. The Lifesavers Conference is a national ... injuries on our nation,s roadways. "We are excited to ...
... Urged to Register with Safe and Well WASHINGTON, March 27 ... North Dakota and Minnesota today to staff shelters that will be ... levees as it rises to record heights. Projections are that the ... feet above flood stage, and the National Weather Service reports water ...
... 27 Zydus Pharmaceuticals announced today that it has ... Administration (FDA) for its Abbreviated New Drug Application (ANDA) ... This product is available for immediate shipment.Topiramate tablets ... years old or older with partial onset or primary ...
... NYU School of Medicine have been named Early Career ... honorees, Iannis Aifantis, Ph.D. associate professor of pathology, co-director ... Cancer Institute and Jeremy S. Dasen Ph.D., assistant professor ... are among 50 of the nation,s top scientists being ...
Cached Medicine News:Health News:HCLA Releases Report on Status of Medical Liability Reform 2Health News:Scientists Capture HIV Transfer Among T-Cells on Video 2Health News:Innocorp, ltd. to Attend Lifesavers Conference 2Health News:Red Cross Readies Shelters As Flood Waters Threaten to Top Levees 2Health News:2 NYU scientists named Howard Hughes Medical Institute's Early Career Scientists 2Health News:2 NYU scientists named Howard Hughes Medical Institute's Early Career Scientists 3
... CARDIAC proBNP assay is a rapid and accurate ... reader system assisting the diagnosis and assessment of ... is both speed and accuracy profit ... CARDIAC proBNP assay = 12 minutes. In emergency ...
The SJM Sguin annuloplasty ring, a semi-rigid ring, is constructed of a one-piece solid core of ultra-high-weight polyethylene enclosed in a knitted polyester sewing cuff....
Intermittent catheter...
... to a new dimension in vitreoretinal ... tool composed of purified perfluoro-n-octane, you ... Perfluoron is ideal for managing retinal ... retinal tears and trauma. , ,Certified ...
Medicine Products: